loading page

Clinical Findings and Treatments of 21 Children with COVID‐19: A Comparison with Their Families
  • +8
  • Herui Li,
  • Yiming Ma,
  • Zihang Zeng,
  • Huihui Zeng,
  • Zhiguo Zhou,
  • Qimi Liu,
  • Peng Huang,
  • Wenlong Liu,
  • Mingyan Jiang,
  • Ping Chen,
  • Yan Chen
Herui Li
Second Xiangya Hospital
Author Profile
Yiming Ma
Second Xiangya Hospital
Author Profile
Zihang Zeng
Second Xiangya Hospital
Author Profile
Huihui Zeng
Second Xiangya Hospital
Author Profile
Zhiguo Zhou
First Hospital of Changsha
Author Profile
Qimi Liu
The second people's hospital of Guilin
Author Profile
Peng Huang
Zhuzhou Central Hospital
Author Profile
Wenlong Liu
Yueyang Second People’s Hospital
Author Profile
Mingyan Jiang
Xiangtan Central Hospital
Author Profile
Ping Chen
Second Xiangya Hospital
Author Profile
Yan Chen
Second Xiangya Hospital
Author Profile

Abstract

Objective: To deepen the understanding of clinical characteristics of pediatric patients with COVID-19. Methods: Retrospective analysis was executed among 21 children and their 38 families with laboratory-conformed novel coronavirus disease in five designated hospitals. Results: In total of 21 children (10 males and 11 females) aged from 1 to 17 years, 90.5% were from 18 family clusters and admitted to designated hospitals 2 days after illness onset, shorter than the adults. Besides 5 asymptomatic cases, pediatric patients mainly performed as fever (66.7%), cough (19.0%) and expectoration (14.3%). Among the 38 adult patients, the major symptoms included fever (63.2%), cough (63.2%), expectoration (44.7%), fatigue (6.8%), chill (15.8%) and dizziness (15.8%). Most cases had normal (76.2%, 68.4%) or decreased (19.0%, 26.3%) leucocytes, nearly half of children showed decreased neutrophils. 15 children and 32 adults had pulmonary involvement, consisted of ground-glass opacity (57.1%, 60.5%), spots (14.3%, 23.7%), stripes (14.3%, 7.9%) and patchy shadow (9.5%, 36.8%). All adults received antiviral therapy: lopinavir/ritonavir (92.1%), interferon (76.3%), arbidol (71.1%), chloroquine (18.4%) and ribavirin (10.5%). 16 children used interferon; 12 took lopinavir/ritonavir; 7 were given arbidol; two received ribavirin. All patients had been recovered and discharged with duration of admission 4-47 days (median 17 days). Conclusions: Pediatric patients with COVID-19 presented as milder symptoms and limited lung lesions than adults. Laboratory abnormalities were atypical in mild patients, neutropenia may be a potential characteristic of children. Efficiency of antiviral therapy need to be further investigated.